Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Ou YC, Tang Z, Novotny W, Cohen A, et al. Leuk Lymphoma 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.

Read + Share

Amedeo Smart

Independent Medical Education

Ou YC, Tang Z, Novotny W, Cohen A, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.
PMID: 34159878